Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,956,409
  • Shares Outstanding, K 55,219
  • Annual Sales, $ 607,520 K
  • Annual Income, $ 1,320 K
  • EBIT $ 140 M
  • EBITDA $ 225 M
  • 60-Month Beta 0.90
  • Price/Sales 3.22
  • Price/Cash Flow 22.35
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 46.97% ( +2.19%)
  • Historical Volatility 22.99%
  • IV Percentile 39%
  • IV Rank 48.22%
  • IV High 82.11% on 07/22/24
  • IV Low 14.25% on 05/31/24
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 686
  • Open Int (30-Day) 919

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.38
  • Number of Estimates 2
  • High Estimate 0.43
  • Low Estimate 0.33
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +1,800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.38 +2.47%
on 12/20/24
37.62 -6.35%
on 12/09/24
-0.99 (-2.73%)
since 11/22/24
3-Month
29.74 +18.46%
on 09/25/24
39.37 -10.52%
on 11/05/24
+3.81 (+12.13%)
since 09/23/24
52-Week
25.53 +37.99%
on 06/14/24
39.37 -10.52%
on 11/05/24
+6.00 (+20.53%)
since 12/22/23

Most Recent Stories

More News
Supernus Pharmaceuticals' CEO to Speak at 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals' CEO will speak at the Piper Sandler Healthcare Conference on December 4, 2024.Quiver AI SummarySupernus Pharmaceuticals, Inc. announced that President and CEO Jack A. Khattar...

SUPN : 35.37 (-0.17%)
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

SUPN : 35.37 (-0.17%)
Supernus Pharmaceuticals' CEO Jack Khattar to Speak at Jefferies London Healthcare Conference on November 20, 2024

Supernus Pharmaceuticals announced CEO Jack Khattar will participate in a fireside chat at the Jefferies London Healthcare Conference.Quiver AI SummarySupernus Pharmaceuticals, Inc. announced that its...

SUPN : 35.37 (-0.17%)
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

SUPN : 35.37 (-0.17%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 35.37 (-0.17%)
Supernus Announces Third Quarter 2024 Financial Results

SUPN : 35.37 (-0.17%)
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

SUPN : 35.37 (-0.17%)
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

SUPN : 35.37 (-0.17%)
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

SUPN : 35.37 (-0.17%)
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

SUPN : 35.37 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 38.26
2nd Resistance Point 37.28
1st Resistance Point 36.35
Last Price 35.37
1st Support Level 34.44
2nd Support Level 33.46
3rd Support Level 32.53

See More

52-Week High 39.37
Last Price 35.37
Fibonacci 61.8% 34.08
Fibonacci 50% 32.45
Fibonacci 38.2% 30.82
52-Week Low 25.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar